Insulin and Carbohydrate Dysregulation
Patients with human immunodeficiency virus receiving highly active antiretroviral therapy (HAART) may experience abnormal body composition changes as well as metabolic abnormalities, including dyslipidemia, increases in triglycerides, low high-density lipoprotein cholesterol levels, and abnormal car...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2003-04, Vol.36 (Supplement-2), p.S91-S95 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S95 |
|---|---|
| container_issue | Supplement-2 |
| container_start_page | S91 |
| container_title | Clinical infectious diseases |
| container_volume | 36 |
| creator | Gelato, Marie C. |
| description | Patients with human immunodeficiency virus receiving highly active antiretroviral therapy (HAART) may experience abnormal body composition changes as well as metabolic abnormalities, including dyslipidemia, increases in triglycerides, low high-density lipoprotein cholesterol levels, and abnormal carbohydrate metabolism, ranging from insulin resistance with and without glucose intolerance to frank diabetes. Whether the body composition changes (i.e., increased visceral adiposity and fat wasting in the peripheral tissues) are linked to abnormalities in carbohydrate metabolism is unclear. The use of HAART with and without therapy with protease inhibitors (PIs) is related to carbohydrate abnormalities and changes in body composition. Regimens that include PIs appear to have a higher incidence of insulin resistance (up to 90%) and diabetes mellitus (up to 40%). The etiology of these abnormalities is not well understood; what is known about insulin and carbohydrate dysregulation with HAART is discussed. |
| doi_str_mv | 10.1086/367564 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_73128642</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>41581031</jstor_id><sourcerecordid>41581031</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-6782e8154a54188be79d40334790cca50fed77ba0fa6ef8614bea3498d0e349c3</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRrFb9B0pPvUV3st9HiR-tFKRUQbwsm2SjqWlSdxOw_96VlOrN0ww8D-8wL0JngC8BS35FuGCc7qEjYEREnCnYDztmMqKSyAE69n6JMYDE7BANIOYsJkIcofG09l1V1iNT56PEuLR53-TOtHZ0s_HOvnWVacumPkEHham8Pd3OIXq-u31KJtHs8X6aXM-ijCjZRlzI2Epg1DAKUqZWqJxiQqhQOMsMw4XNhUgNLgy3heRAU2sIVTLHNoyMDNG4z1275rOzvtWr0me2qkxtm85rQSCWnMb_iuE6V1T8ETPX-PBRodeuXBm30YD1T3W6ry6IF9vELl3Z_FfbdhWE815Y-rZxO06BScAEAo96XvrWfu24cR-aCyKYnry86kWczNUCz_UD-Qb_w372</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18869472</pqid></control><display><type>article</type><title>Insulin and Carbohydrate Dysregulation</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><source>Oxford Journals</source><creator>Gelato, Marie C.</creator><creatorcontrib>Gelato, Marie C.</creatorcontrib><description>Patients with human immunodeficiency virus receiving highly active antiretroviral therapy (HAART) may experience abnormal body composition changes as well as metabolic abnormalities, including dyslipidemia, increases in triglycerides, low high-density lipoprotein cholesterol levels, and abnormal carbohydrate metabolism, ranging from insulin resistance with and without glucose intolerance to frank diabetes. Whether the body composition changes (i.e., increased visceral adiposity and fat wasting in the peripheral tissues) are linked to abnormalities in carbohydrate metabolism is unclear. The use of HAART with and without therapy with protease inhibitors (PIs) is related to carbohydrate abnormalities and changes in body composition. Regimens that include PIs appear to have a higher incidence of insulin resistance (up to 90%) and diabetes mellitus (up to 40%). The etiology of these abnormalities is not well understood; what is known about insulin and carbohydrate dysregulation with HAART is discussed.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/367564</identifier><identifier>PMID: 12652377</identifier><language>eng</language><publisher>United States: The University of Chicago Press</publisher><subject>Anti-HIV Agents - therapeutic use ; Antiretroviral Therapy, Highly Active ; Body fat ; Carbohydrate Metabolism ; Diabetes mellitus ; Highly active antiretroviral therapy ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; Humans ; Insulin ; Insulin - metabolism ; Insulin resistance ; Lipodystrophy ; Memory interference ; Metabolic Diseases - diet therapy ; Metabolic Diseases - epidemiology ; Metabolic Diseases - etiology ; Metabolic Diseases - mortality ; Morbidity ; Mortality ; Nutritional Physiological Phenomena ; Protease inhibitors ; Type 2 diabetes mellitus</subject><ispartof>Clinical infectious diseases, 2003-04, Vol.36 (Supplement-2), p.S91-S95</ispartof><rights>2003 Infectious Diseases Society of America</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-6782e8154a54188be79d40334790cca50fed77ba0fa6ef8614bea3498d0e349c3</citedby><cites>FETCH-LOGICAL-c398t-6782e8154a54188be79d40334790cca50fed77ba0fa6ef8614bea3498d0e349c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/41581031$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/41581031$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27903,27904,57995,58228</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12652377$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gelato, Marie C.</creatorcontrib><title>Insulin and Carbohydrate Dysregulation</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><description>Patients with human immunodeficiency virus receiving highly active antiretroviral therapy (HAART) may experience abnormal body composition changes as well as metabolic abnormalities, including dyslipidemia, increases in triglycerides, low high-density lipoprotein cholesterol levels, and abnormal carbohydrate metabolism, ranging from insulin resistance with and without glucose intolerance to frank diabetes. Whether the body composition changes (i.e., increased visceral adiposity and fat wasting in the peripheral tissues) are linked to abnormalities in carbohydrate metabolism is unclear. The use of HAART with and without therapy with protease inhibitors (PIs) is related to carbohydrate abnormalities and changes in body composition. Regimens that include PIs appear to have a higher incidence of insulin resistance (up to 90%) and diabetes mellitus (up to 40%). The etiology of these abnormalities is not well understood; what is known about insulin and carbohydrate dysregulation with HAART is discussed.</description><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral Therapy, Highly Active</subject><subject>Body fat</subject><subject>Carbohydrate Metabolism</subject><subject>Diabetes mellitus</subject><subject>Highly active antiretroviral therapy</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>Humans</subject><subject>Insulin</subject><subject>Insulin - metabolism</subject><subject>Insulin resistance</subject><subject>Lipodystrophy</subject><subject>Memory interference</subject><subject>Metabolic Diseases - diet therapy</subject><subject>Metabolic Diseases - epidemiology</subject><subject>Metabolic Diseases - etiology</subject><subject>Metabolic Diseases - mortality</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Nutritional Physiological Phenomena</subject><subject>Protease inhibitors</subject><subject>Type 2 diabetes mellitus</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1Lw0AQhhdRrFb9B0pPvUV3st9HiR-tFKRUQbwsm2SjqWlSdxOw_96VlOrN0ww8D-8wL0JngC8BS35FuGCc7qEjYEREnCnYDztmMqKSyAE69n6JMYDE7BANIOYsJkIcofG09l1V1iNT56PEuLR53-TOtHZ0s_HOvnWVacumPkEHham8Pd3OIXq-u31KJtHs8X6aXM-ijCjZRlzI2Epg1DAKUqZWqJxiQqhQOMsMw4XNhUgNLgy3heRAU2sIVTLHNoyMDNG4z1275rOzvtWr0me2qkxtm85rQSCWnMb_iuE6V1T8ETPX-PBRodeuXBm30YD1T3W6ry6IF9vELl3Z_FfbdhWE815Y-rZxO06BScAEAo96XvrWfu24cR-aCyKYnry86kWczNUCz_UD-Qb_w372</recordid><startdate>20030401</startdate><enddate>20030401</enddate><creator>Gelato, Marie C.</creator><general>The University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20030401</creationdate><title>Insulin and Carbohydrate Dysregulation</title><author>Gelato, Marie C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-6782e8154a54188be79d40334790cca50fed77ba0fa6ef8614bea3498d0e349c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral Therapy, Highly Active</topic><topic>Body fat</topic><topic>Carbohydrate Metabolism</topic><topic>Diabetes mellitus</topic><topic>Highly active antiretroviral therapy</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>Humans</topic><topic>Insulin</topic><topic>Insulin - metabolism</topic><topic>Insulin resistance</topic><topic>Lipodystrophy</topic><topic>Memory interference</topic><topic>Metabolic Diseases - diet therapy</topic><topic>Metabolic Diseases - epidemiology</topic><topic>Metabolic Diseases - etiology</topic><topic>Metabolic Diseases - mortality</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Nutritional Physiological Phenomena</topic><topic>Protease inhibitors</topic><topic>Type 2 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gelato, Marie C.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gelato, Marie C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin and Carbohydrate Dysregulation</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clinical Infectious Diseases</addtitle><date>2003-04-01</date><risdate>2003</risdate><volume>36</volume><issue>Supplement-2</issue><spage>S91</spage><epage>S95</epage><pages>S91-S95</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Patients with human immunodeficiency virus receiving highly active antiretroviral therapy (HAART) may experience abnormal body composition changes as well as metabolic abnormalities, including dyslipidemia, increases in triglycerides, low high-density lipoprotein cholesterol levels, and abnormal carbohydrate metabolism, ranging from insulin resistance with and without glucose intolerance to frank diabetes. Whether the body composition changes (i.e., increased visceral adiposity and fat wasting in the peripheral tissues) are linked to abnormalities in carbohydrate metabolism is unclear. The use of HAART with and without therapy with protease inhibitors (PIs) is related to carbohydrate abnormalities and changes in body composition. Regimens that include PIs appear to have a higher incidence of insulin resistance (up to 90%) and diabetes mellitus (up to 40%). The etiology of these abnormalities is not well understood; what is known about insulin and carbohydrate dysregulation with HAART is discussed.</abstract><cop>United States</cop><pub>The University of Chicago Press</pub><pmid>12652377</pmid><doi>10.1086/367564</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2003-04, Vol.36 (Supplement-2), p.S91-S95 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73128642 |
| source | Jstor Complete Legacy; MEDLINE; EZB Electronic Journals Library; Oxford Journals |
| subjects | Anti-HIV Agents - therapeutic use Antiretroviral Therapy, Highly Active Body fat Carbohydrate Metabolism Diabetes mellitus Highly active antiretroviral therapy HIV HIV Infections - complications HIV Infections - drug therapy Humans Insulin Insulin - metabolism Insulin resistance Lipodystrophy Memory interference Metabolic Diseases - diet therapy Metabolic Diseases - epidemiology Metabolic Diseases - etiology Metabolic Diseases - mortality Morbidity Mortality Nutritional Physiological Phenomena Protease inhibitors Type 2 diabetes mellitus |
| title | Insulin and Carbohydrate Dysregulation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T18%3A30%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin%20and%20Carbohydrate%20Dysregulation&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Gelato,%20Marie%20C.&rft.date=2003-04-01&rft.volume=36&rft.issue=Supplement-2&rft.spage=S91&rft.epage=S95&rft.pages=S91-S95&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1086/367564&rft_dat=%3Cjstor_proqu%3E41581031%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18869472&rft_id=info:pmid/12652377&rft_jstor_id=41581031&rfr_iscdi=true |